CVKD - Cadrenal Therapeutics, Inc.
Previous close
16.27
1.780 10.940%
Share volume: 0
Last Updated: Thu 26 Dec 2024 08:13:30 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.30%
PREVIOUS CLOSE
CHG
CHG%
$14.49
1.78
12.28%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
3.58%
1 Month
7.73%
3 Months
1.79%
6 Months
3,042.55%
1 Year
2,585.45%
2 Year
258.50%
Key data
Stock price
$16.27
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.41 - $19.97
52 WEEK CHANGE
$1,974.15
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Quang Pham
Region: US
Website: www.cadrenal.com
Employees: 0
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: www.cadrenal.com
Employees: 0
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
We are focused on developing tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease, or ESRD, and atrial fibrillation (irregular heartbeat), or AFib. Our principal executive offices are located at 822 A1A North, Suite 306, Ponte Vedra, Florida.
Recent news